Neurvati Neurosciences

During the World Orphan Drug Congress in Boston, our SVP of Corporate and Business Development, Jason Lettiere, will join industry leaders for a panel discussion on "Unveiling Promising Strategies: Drug Discovery for Rare Disease Treatments." While significant progress has been made in the #raredisease space, there remains an urgent need for more effective treatments, especially for neurological disorders. At GRIN Therapeutics, Inc., we are focused on advancing drug discovery by developing precision therapeutics that address these critical unmet needs. Join us as we engage with top pharma and biotech experts to explore the opportunities and challenges in orphan drug development. See the agenda: https://lnkd.in/e5kKW7bx #WODC #WorldOrphanDrugCongress

Recent advances in the treatment of developmental and epileptic encephalopathies (DEE) and pediatric epilepsies have been significantly shaped by the emergence of whole exome sequencing. This technology enables precise genetic diagnoses, allowing clinicians to move beyond the traditional empirical treatment approach, where broad spectrum antiseizure medicines were prescribed based on symptoms rather than addressing the underlying disease-specific biology. By identifying the genetic variants behind these disorders, whole exome sequencing is opening the door to the development of targeted therapies, offering more personalized treatment options. We’re proud to be at the forefront, advancing research in precision therapeutics for neurodevelopmental disorders. Learn more about pediatric epilepsies from the American Academy of Pediatrics: https://lnkd.in/eXTWcne9

Collaboration and partnerships are essential in advancing #neuroscience research, enabling us to tackle complex challenges and drive innovation. Our SVP of Corporate and Business Development, Jason Lettiere, discusses the pivotal role these collaborations can play in accelerating the development of breakthrough treatments for neurological and neuropsychiatric disorders.

We’re looking forward to having our Chief Medical Officer Michael Panzara join the panel celebrating the National Institute of Neurological Disorders and Stroke (NINDS)'s 75th anniversary at the American Academy of Neurology Meeting, taking place April 5-9 in San Diego. Dr. Panzara will discuss what neurology will look like in the next 10 years and the changes he hopes to see in the field going forward. It’s an exciting opportunity to explore the future of neurology, the evolving role of NINDS, and how innovation and collaboration will shape the next era of neurological care and research. Better treatments for neurological diseases remain one of the largest opportunities in modern medicine, and #AANAM will serve as a critical driver of progress in the field. See the agenda: https://lnkd.in/ebx_cQFD

The European Medicines Agency (EMA) has granted PRIME designation to our investigational drug, radiprodil, which is being developed for the treatment of GRIN-related neurodevelopmental disorder (NDD). PRIME is given in recognition of priority medicines that have demonstrated potential to target an unmet need to a significant extent. As planning progresses for our pivotal global Phase 3 trial in the middle of this year, we remain committed to partnering with patients, caregivers, advocacy groups, and the research community to move this work forward.

#PurpleDay reminds us of the ongoing need to raise awareness, advocate for research, and create a future where those impacted by #Epilepsy are better understood and supported.    We are honored to have supported the Epilepsy Foundation and their Epilepsy Research Ambassador Bootcamp at the annual National Epilepsy Walk in DC earlier this month.     And as our progress continues, we stand committed to collaborating with patients, families, and advocates in advancing targeted therapies for developmental and epileptic encephalopathies (DEEs), including GRIN-related neurodevelopmental disorder (NDD), tuberous sclerosis complex (#TSC), and focal cortical dysplasia Type II (#FCD). 

Join our team at the Stifel Virtual CNS Forum to learn about the exciting progress we’re making in advancing development of precision therapeutics for neurodevelopmental disorders. We’ll be sharing insights on our pipeline, highlighting key developments, and discussing how we’re positioning ourselves to address critical unmet needs in the #CNS space.

Another exciting milestone for GRIN Therapeutics, Inc.! This follows the recent Breakthrough Therapy designation received from FDA for investigational radiprodil and reinforces our commitment to advancing research in this area of high unmet need. As we prepare to initiate our Phase 3 pivotal trial, we are grateful for the patients and families without whom our work would not be possible and the continued collaboration of advocacy groups and clinicians who support this important work.

Delighted to share that our CEO Bruce Leuchter, M.D., will be attending this year’s Leerink Partners Global #Biopharma Conference from March 9-12 in Miami. We look forward to taking part in sharing market insights and strategic guidance among institutional investors, #healthcare industry experts, and policymakers alike.

This #GRINAwarenessMonth, we reflect on the progress being made to better understand GRIN-related NDD, which was first characterized in 2010 and formally named in 2014. At GRIN Therapeutics, Inc., we are committed to advancing precision therapeutics for the potential treatment of GRIN-related NDD. The recent Breakthrough Therapy designation we received for treatment of seizures associated with this disorder highlights the potential for this treatment option. As we prepare for our pivotal Phase 3 trial, we are excited to continue working with the GRIN community to bring hope and new possibilities.